View Post

Study finds new way to make chemotherapy more effective against pancreatic cancer

In Clinical Trials by Barbara Jacoby

By: Jay Furst From: mayoclinic.org Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs. A Mayo Clinic-led study published today opens a promising new front in that battle. Using patient cell lines and tumor-bearing models, researchers found that inhibition …

View Post

Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical’s Phase 2 Clinical Trial

In Clinical Trials by Barbara Jacoby

Source: AIVITA Biomedical From: PR Newswire AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated data from its ongoing glioblastoma Phase 2 clinical trial investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells. In approximately 80% of treated patients, sequential blood plasma biomarker analyses have identified the induction of a type II hypersensitivity response, followed by …

View Post

CDK4/6 Inhibitors Significantly Improved OS in Women With Advanced Breast Cancer, Studies Show

In Clinical Trials by Barbara Jacoby

By: Laura Joszt From: ajmc.com Pairing a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor with fulvestrant significantly improved overall survival (OS) for women with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer, according to 2 abstracts presented at the European Society of Medical Oncology 2019 Congress. Women with hormone receptor (HR)-positive, human epidermal growth factor 2 …

View Post

FDA Approves Acalabrutinib for CLL

In Clinical Trials by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The FDA has approved acalabrutinib (Calquence) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The approval, which was done under the FDA’s Project Orbis initiative, was based on 2 phase III randomized trials—ELEVATE-TN and ASCEND. “Today, as part of a US, Australian, and Canadian collaboration known …

View Post

Abemaciclib Triplet Prolongs PFS in HR+/HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com The triplet combination of abemaciclib (Verzenio), trastuzumab (Herceptin), and fulvestrant (Faslodex) showed a significant statistical improvement in progression-free survival (PFS) compared with chemotherapy and trastuzumab in patients with heavily pretreated, hormone receptor (HR)–positive, HER2-positive breast cancer, according to the results of the phase II monarcHER trial. MonarcHER was designed to highlight signals of response with …

View Post

AstraZeneca Receives FDA Priority Review For Breast Cancer Drug

In Clinical Trials by Barbara Jacoby

Source: AstraZeneca From: pharmavoice.com AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab. The Prescription Drug User Fee Fact (PDUFA) date for trastuzumab deruxtecan, an HER-2 targeting antibody drug conjugate and potential new medicines for the treatment of HER2-positive metastic breast cancer is set for the second quarter of 2020. José …

View Post

I-SPY 2 Breast Cancer Clinical Trial Coming To Wake Forest Baptist Health

In Clinical Trials by Barbara Jacoby

By: Carrie Hodgin, WFMY News 2 Digital From: wfmynews2.com An innovative breast cancer clinical trial is coming to Wake Forest Baptist Health. It’s available to patients with early-stage, high-risk for recurrence breast cancer. It’s called the I-SPY 2 TRIAL. It will allow for every patient’s data to contribute real-time information so that the next similar patient receives the best treatment …

View Post

Intraoperative radiation therapy is promising treatment for early-stage breast cancer

In Clinical Trials by Barbara Jacoby

By: Dr. Shayna Showalter From: dailyprogress.com Women with early-stage breast cancer are often treated with breast-conserving surgery followed by whole-breast irradiation (WBI). However, WBI is burdensome, requiring four to six weeks of daily treatments. It also exposes healthy areas of the body — namely, the heart, lungs and skin — to radiation. As a result, studies have shown that women …

View Post

Giving birth young helps protect women from breast cancer. Could a drug mimic that?

In Clinical Trials by Barbara Jacoby

By: Marie McCullough, The Philadelphia Inquirer From: globegazette.com – Having a baby before age 20 markedly cuts a woman’s lifetime chance of developing breast cancer, studies show. – What if young women could take a drug that would mimic that cancer-preventing effect of full-term pregnancy? – Fox Chase Cancer Center researcher Jose Russo, 77, is inspired and driven by that …